Holzer G, Riegler E, Hönigsmann H, Farokhnia S, Schmidt J B
Division of Special and Environmental Dermatology, Medical University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria.
Br J Dermatol. 2005 Sep;153(3):626-34. doi: 10.1111/j.1365-2133.2005.06685.x.
For many years topical progesterone has been prescribed by gynaecologists as an antiageing and skin-firming treatment, without any clinical scientific evidence of its effects, tolerability and safety when applied to skin.
To evaluate the influence of 2% progesterone cream on function and texture of the skin in peri- and postmenopausal women.
A double-blind, randomized, vehicle-controlled study was conducted in 40 subjects. Objective methods for measuring skin elasticity, epidermal hydration and skin surface lipids, clinical monitoring and self-assessment, and determination of blood hormone levels (luteinizing hormone, follicle-stimulating hormone, oestrogen and progesterone) were used to determine effects and side-effects of this treatment at four visits over a 16-week period.
The study demonstrated a significant (P < or = 0.05) increase of the elastic skin properties in the treatment group, as demonstrated by objective measurements of three skin elasticity parameters, whereas in the control group no such effect was observed. This effect in the treatment group was further paralleled by the results of the clinical monitoring, where the 2% progesterone cream yielded consistent superiority over vehicle in counteracting different signs of ageing in the skin of peri- and postmenopausal women. Clinical monitoring showed a greater reduction in wrinkle counts (29.10% vs. 16.50%) and wrinkle depth (9.72% vs. 7.35%) around the right eye, a greater decrease in nasolabial wrinkle depth (9.72% vs. 6.62%) and a significantly higher (P < 0.05) increase in skin firmness (23.61% vs. 13.24%) in the treatment group. Epidermal hydration and skin surface lipids did not change significantly in either group during the study. Progesterone was well absorbed in the systemic circulation: mean blood levels rose minimally, but statistically significantly (P = 0.001), by 0.53 ng mL(-1). No serious side-effects of the treatment were observed.
The results of this study demonstrate that topical 2% progesterone acts primarily in increasing elasticity and firmness in the skin of peri- and postmenopausal women. These effects in combination with good tolerability make progesterone a possible treatment agent for slowing down the ageing process of female skin after onset of the menopause.
多年来,妇科医生一直将外用黄体酮作为一种抗老化和紧致肌肤的治疗方法,但在应用于皮肤时,其效果、耐受性和安全性并无任何临床科学依据。
评估2%黄体酮乳膏对围绝经期和绝经后女性皮肤功能及质地的影响。
对40名受试者进行了一项双盲、随机、赋形剂对照研究。在16周内进行4次访视,采用测量皮肤弹性、表皮水合作用和皮肤表面脂质的客观方法、临床监测和自我评估,以及测定血液激素水平(促黄体生成素、促卵泡激素、雌激素和黄体酮)来确定该治疗的效果和副作用。
研究表明,通过对三个皮肤弹性参数的客观测量,治疗组皮肤弹性特性显著增加(P≤0.05),而对照组未观察到这种效果。治疗组的这种效果在临床监测结果中也得到了进一步体现,在抵消围绝经期和绝经后女性皮肤不同老化迹象方面,2%黄体酮乳膏比赋形剂具有持续的优势。临床监测显示,治疗组右眼周围的皱纹数量减少更多(29.10%对16.50%),皱纹深度减少更多(9.72%对7.35%),鼻唇沟皱纹深度减少更多(9.72%对6.62%),皮肤紧致度显著更高(P<0.05)增加(23.61%对13.24%)。在研究期间,两组的表皮水合作用和皮肤表面脂质均无显著变化。黄体酮在体循环中吸收良好:平均血液水平略有上升,但具有统计学意义(P = 0.001),上升了0.53 ng/mL。未观察到该治疗的严重副作用。
本研究结果表明,外用2%黄体酮主要作用是增加围绝经期和绝经后女性皮肤的弹性和紧致度。这些效果与良好的耐受性相结合,使黄体酮成为绝经后减缓女性皮肤衰老过程的一种可能的治疗药物。